"The Supreme Court's decision to grant certiorari reflects something broader: a continued focus on lowering drug prices through faster generic entry, even at the risk of undermining the patent incentives that make pharmaceutical innovation possible."
"Since 1984, pharmaceutical competition has been shaped by the Hatch-Waxman Act—a statute designed to balance innovation and generic entry. The premise was straightforward: generics would enter efficiently after patent expiration, while patent term restoration and regulatory exclusivities would preserve incentives for innovation."
"In practice, that balance has proven far more difficult to maintain. Rather than a streamlined system, Hatch-Waxman has produced a dense legal environment characterized by strategic behavior on all sides."
The Supreme Court's decision to hear Hikma v. Amarin addresses whether a generic drug manufacturer can be liable for inducing patent infringement through marketing. This case highlights a broader concern regarding drug pricing and the implications for patent incentives that support pharmaceutical innovation. The Hatch-Waxman Act, intended to balance innovation and generic entry, has led to a complex legal environment with strategic behaviors from both brand and generic manufacturers, complicating the intended balance of competition and innovation.
Read at IPWatchdog.com | Patents & Intellectual Property Law
Unable to calculate read time
Collection
[
|
...
]